ClinicalTrials.gg
CompletedNCT04406402Updated Jun 2, 2020

L-arginine and Asymmetric Dimethylarginine (ADMA) and Lifestyle Protocols

An interventional study of Acute dietary protocols and lifestyle modification in Diabetes Mellitus, Type 2, Obesity and Arginine, sponsored by Tel-Aviv Sourasky Medical Center. Completed at 1 site in Israel. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2020-06-02.

Sponsored by Tel-Aviv Sourasky Medical Center · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 13 years 5 months after the study started (first participant enrolled Dec 2006, registered May 2020).
Phase
Not applicable
Study type
Interventional
Enrollment
243
Allocation
Non-randomized
Ages
40 Years and older
Sex
All
01

Study summary

Low serum L-arginine (Arg) and high asymmetric dimethylarginine (ADMA) can predict microvascular complications in type 2 diabetes (T2DM). The investigators examined whether or not Arg and ADMA are affected by dietary factors or lifestyle modification in overweight/ obese and T2DM subjects.

Read the detailed description

The investigators tested the effects on serum Arg and ADMA of a) a single load of ingested dextrose, protein, fat or alcohol, each consumed within 10 minutes; b) a single episode of physical exercise; c) a 12 weeks lifestyle modification program comprised of a standard dietary and physical activity counseling in obese or T2DM subjects on circulating Arg and ADMA (n=43)

02

Conditions studied

  • Diabetes Mellitus, Type 2
  • Obesity
  • Arginine
  • Asymmetric Dimethylarginine
03

In context

Diabetes Mellitus, Type 2

9,590 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,332 are open to participants now.

This study's enrollment of 243 is above the median of 81 across 7,713 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Tel-Aviv Sourasky Medical Center is the lead sponsor of 553 studies on the registry; 50 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obese and/ or T2DM subjects

Exclusion criteria

Exclusion Criteria:

  • type 1 diabetes
  • insulin-treated T2DM
  • active coronary disease (recent [≤ 6months] myocardial infarction, unstable angina, recent coronary catheterization, or coronary bypass grafting
  • individuals with significant impairment in liver enzymes (≥ 2.5 the upper limit of the normal range)
  • serum creatinine higher than 1.5mg%
  • known malabsorption, alcoholism or illicit use of drugs
  • abnormal thyroid function tests
  • concomitant or recent use of glucocorticoids
  • uncertain mental state (to avoid invalid informed consent or lack of compliance).
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Single group
Masking
Single (Outcomes assessor)
Enrollment
243 participants (actual)

Study arms

  • Experimental
    Acute glucose tolerance test

    A standard oral glucose tolerance test (75 grams of dextrose in 180 cc of water)

    Behavioral: Acute dietary protocols and lifestyle modification

  • Experimental
    Acute protein load test

    A protein-rich, vanilla-flavored powder (Pro-gym, Telpharma, Is

    Behavioral: Acute dietary protocols and lifestyle modification

  • Experimental
    Acute fat load test

    a 100-gram portion of sweet cream containing 300 Kacls, of which 94% of the ingested calories were fat

    Behavioral: Acute dietary protocols and lifestyle modification

  • Experimental
    Acute alcohol load test

    Vodka (100 cc, 40% alcohol)

    Behavioral: Acute dietary protocols and lifestyle modification

  • Experimental
    Acute exercise

    30 minutes of supervised graded walking on a treadmill according to each subject's individual ability. A goal heart rate was calculated as 70% of the age-adjusted maximal allowable heart rate.

    Behavioral: Acute dietary protocols and lifestyle modification

  • Experimental
    Lifestyle modification program - 12 weeks

    12 weeks of weight-loss dietary program constructed according to the guidelines of the American Diabetes Association. Based on weight, gender, and age, daily dietary allowance varied at 1200-1800 Kcal, 50% carbohydrates, 20% protein, and 30% fat. Participants were also asked to engage in moderate physical activity comprised of a 40-minute walk three times a week. A weekly clinic visit alternating with a weekly telephone contact was also required.

    Behavioral: Acute dietary protocols and lifestyle modification

Interventions

  • BehavioralAcute dietary protocols and lifestyle modification

    The investigators tested the effects on serum Arg and ADMA of a) a single load of ingested dextrose, protein, fat or alcohol, each consumed within 10 minutes; b) a single episode of physical exercise; c) a 12 weeks lifestyle modification program comprised of a standard dietary and physical activity counseling in obese or T2DM subjects on circulating Arg and ADMA (n=43).

06

What researchers measure

Primary outcomes

  1. Serum L-arginine change

    Change in arginine levels (absolute and relative) (µmol/l)

    Time frame: For acute phase: before the nutritional/exercise load (time 0), as well as 30, 60, 90, 120 and 150 minutes after the challenge test. And from baseline to 12 weeks for lifestyle modification phase

  2. High asymmetric dimethylarginine (ADMA) change

    Change in ADMA levels (absolute and relative) (µmol/l)

    Time frame: For acute phase: before the nutritional/exercise load (time 0), as well as 30, 60, 90, 120 and 150 minutes after the challenge test. And from baseline to 12 weeks for lifestyle modification phase

Secondary outcomes

  1. Body mass index (BMI) change

    Change in BMI levels (Kg/m2)

    Time frame: From baseline to 12 weeks for lifestyle modification phase

  2. Glycated hemoglobin (HbA1c) change

    Change in HbA1c levels (%)

    Time frame: From baseline to 12 weeks for lifestyle modification phase

07

Study locations

1 site
  • Diabetes Unit, E. Wolfson Medical Center
    Holon, 5822012, Israel
08

References and documents

Publications

  • Buch A, Ganz T, Wainstein J, Gilad S, Limor R, Shefer G, Boaz M, Stern N. Alcohol Drinks Induce Acute Lowering in Circulating l-Arginine in Obese and Type 2 Diabetic Subjects. J Med Food. 2022 Jun;25(6):675-682. doi: 10.1089/jmf.2021.0045. PubMed 35708634 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2006 to primary completion in Apr 2008, 15 months.

Of 1,924 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 39. This study's 15 months is below that.

Counting every sponsor, half of 2,101 studies reached it within 20 months; a quarter within 10 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2020
First posted
May 28, 2020
StartActual
Dec 5, 2006
Primary completionActual
Apr 4, 2008
CompletionActual
Dec 10, 2008
Last update
Jun 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04406402
Responsible party
Sponsor
First posted
May 28, 2020
Start date
Dec 5, 2006
Primary completion
Apr 4, 2008
Completion
Dec 10, 2008
Last update
Jun 2, 2020

Study contacts

Naftali Stern, MD
principal investigator · Tel-Aviv Sourasky Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion